# US 2025/0146018 A1 · Compositions and methods for impeding transcription of expanded microsatellite repeats

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146018 A1
- Document ID: US20250146018A1
- Status: Published application
- Kind: A1
- Application number: 18/952,458
- Filed: 2024-11-19
- Published: 2025-05-08
- Earliest claimed: 2016-10-31
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Eric Tzy-Shi Wang; Tanvi Saxena; Belinda Pinto; John Andrew Berglund
- Web page: https://patentgrep.com/patent/US20250146018A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 15/86: Viral vectors
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14123: Virus like particles [VLP]
- C12N 2750/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14141: Use of virus, viral particle or viral elements as a vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating diseases characterized by expanded microsatellite repeats by impeding or inhibiting transcription of expanded microsatellite repeats.

## Claims

### Claim 1

A method of treating a disease characterized by expanded microsatellite repeats, the method comprising administering to a subject in need thereof an effective amount of a composition that impedes or inhibits transcription of expanded microsatellite repeats.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition comprises an adeno-associated virus (AAV) vector comprising a nucleic acid encoding a deactivated Cas9 (dCas9), an AAV virion comprising a nucleic acid encoding a dCas9, an AAV viral particle comprising a nucleic acid encoding a dCas9, a small molecule therapeutic, or a combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein said composition further comprises a guide RNA (gRNA).

### Claim 4 (depends on 3)

The method of claim 3, wherein said guide RNA comprises (CAG)6 gRNA (SEQ ID NO:1), (CTG)6 (SEQ ID NO:2) gRNA, (CUG)6 (SEQ ID NO:3) gRNA, (AGC)6 (SEQ ID NO:4) gRNA, (GCA)6 (SEQ ID NO:5) gRNA, (CAGG)5 (SEQ ID NO:6) gRNA, (AGGC)5 (SEQ ID NO:7) gRNA, (GGCA)5 (SEQ ID NO:8) gRNA, (GCAG)5 (SEQ ID NO:9) gRNA, C4G2 gRNA, G4C2 gRNA, (C4G2)3 (SEQ ID NO:10) gRNA, (G4C2)3 (SEQ ID NO:11) gRNA, CAG repeat-targeting gRNA, CTG repeat-targeting gRNA, CCTG repeat-targeting gRNA, CAGG repeat-targeting gRNA, G4C2 repeat-targeting gRNA, C4G2 repeat-targeting gRNA, or a combination thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein said small molecule therapeutic comprises actinomycin D, echinomycin, mythramycin A, or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein said disease comprises myotonic dystrophy type 1, myotonic dystrophy type 2, C9ALS/FTD, spinocerebellar ataxias, Fuch's endothelial corneal dystrophy, or a neurological disorder.
